Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725946 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
A Early Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT00725946: Clinical Trial Early Phase 1 study, sponsored by Stanford University.
NCT00725946 is a Early Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00725946, a Early Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a pilot imaging study for women whose tumors express NIS \[Na+I- symporter, sodium iodide symporter\]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in \> 20% of cells as determined by immunohistochemical methods. A total of 10 patients will be imaged with 124I PET/CT (serial scans over 24 hour period) to determine radioiodide uptake and distribution in tumor tissue. Thyroid iodide uptake and retention will be blocked beginning one week prior to 124I PET/CT scan with thyroid hormone (T3) and methimazole (impedes organification). Tumor, organ and whole body dosimetry will be calculated in each patient.
Interventions
- DRUG Iodine-124
- RADIATION PET/CT with Iodine-124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00725946
The ClinicalTrials.gov registry entry for NCT00725946 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Iodine-124 is the first listed.
NCT00725946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00725946 about?
NCT00725946 is a clinical study titled "Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT". This is a pilot imaging study for women whose tumors express NIS \[Na+I- symporter, sodium iodide symporter\]. Eligibility is limited to the presence of strong (3+) and/or plasma membrane staining in \> 20% of cells as determined by immunohistochemical methods. A total of 10 patients will be imaged ...
What is the current status of trial NCT00725946?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2008-02. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00725946?
The interventions under investigation include: Iodine-124 (DRUG), PET/CT with Iodine-124 (RADIATION).
Who is sponsoring clinical trial NCT00725946?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.